文献速递肝病

巨噬细胞参与小鼠硬化性胆管炎的发病机制

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
PubMed 文献 · J Hepatol · 2018-05-24

研究在小鼠急性(胆管内注射凋亡抑制拮抗剂BV6)和慢性(Mdr2-/-小鼠)硬化性胆管炎模型中,发现胆管周围促炎(M1样)和替代活化(M2样)单核细胞来源巨噬细胞增多,且与损伤发生平行、缓解后逆转。使用CCR2/5拮抗剂CVC或CCR2基因缺失可减轻小鼠巨噬细胞聚集、肝损伤和纤维化,提示单核细胞来源巨噬细胞参与硬化性胆管炎发病并可能成为治疗靶点。

要点

  • PSC患者及两种小鼠硬化性胆管炎模型中均见胆管周围单核细胞来源巨噬细胞浸润,以M1样为主。
  • 小鼠急性硬化性胆管炎中巨噬细胞募集与损伤发生平行,损伤缓解后逆转。
  • CVC治疗或CCR2基因缺失可减轻小鼠巨噬细胞聚集、肝损伤和纤维化。

核心结论

  • 胆管周围募集的巨噬细胞是PSC和急、慢性小鼠硬化性胆管炎模型的特征。
  • 药理学和遗传学抑制胆管周围巨噬细胞募集可减少小鼠肝损伤和纤维化。
  • 作者认为单核细胞来源巨噬细胞参与小鼠硬化性胆管炎和PSC发病,支持其作为治疗靶点的潜力。

研究设计与样本

  • 研究测量了急性(胆管内注射凋亡抑制拮抗剂BV6)和慢性(Mdr2-/-小鼠)硬化性胆管炎小鼠模型的免疫细胞谱、肝巨噬细胞数量、定位与极化、纤维化及血清肝损伤和胆汁淤积标志物。
  • 部分观察在PSC患者肝标本中得到验证。
  • 基于CCR2/CCL2轴在单核/巨噬细胞趋化中的作用,在BV6注射小鼠中评估了CCR2/5拮抗剂cenicriviroc(CVC)治疗或CCR2基因缺失(Ccr2-/-小鼠)的效果。

主要发现

  • 与正常肝脏相比,PSC中胆管周围促炎(M1样)和替代活化(M2样)单核细胞来源巨噬细胞增多。
  • 两种硬化性胆管炎模型中,肝免疫细胞基因谱分析显示单核/巨噬细胞占优势;免疫组化证实胆管周围单核细胞来源巨噬细胞募集(M1多于M2极化),与损伤发生平行,且在急性硬化性胆管炎小鼠缓解后逆转。
  • 体外实验显示,PSC、衰老和BV6处理的人胆管细胞释放单核细胞趋化因子(CCL2、IL-8)和巨噬细胞活化因子。
  • CVC治疗或CCR2基因缺失减弱急性硬化性胆管炎小鼠的巨噬细胞聚集、肝损伤和纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Macrophages contribute to liver disease, but their role in cholestatic liver injury, including primary sclerosing cholangitis (PSC), is unclear. We tested the hypothesis that macrophages contribute to the pathogenesis of, and are therapeutic targets for, PSC. METHODS: Immune cell profile, hepatic macrophage number, localization and polarization, fibrosis, and serum markers of liver injury and cholestasis were measured in an acute (intrabiliary injection of the inhibitor of apoptosis antagonist BV6) and chronic (Mdr2-/- mice) mouse model of sclerosing cholangitis (SC). Selected observations were confirmed in liver specimens from patients with PSC. Because of the known role of the CCR2/CCL2 axis in monocyte/macrophage chemotaxis, therapeutic effects of the CCR2/5 antagonist cenicriviroc (CVC), or genetic deletion of CCR2 (Ccr2-/- mice) were determined in BV6-injected mice. RESULTS: We found increased peribiliary pro-inflammatory (M1-like) and alternatively-activated (M2-like) monocyte-derived macrophages in PSC compared to normal livers. In both SC models, genetic profiling of liver immune cells identified a predominance of monocytes/macrophages; immunohistochemistry confirmed peribiliary monocyte-derived macrophage recruitment (M1>M2-polarized), which paralleled injury onset and was reversed upon resolution in acute SC mice. PSC, senescent and BV6-treated human cholangiocytes released monocyte chemoattractants (CCL2, IL-8) and macrophage-activating factors in vitro. Pharmacological inhibition of monocyte recruitment by CVC treatment or CCR2 genetic deletion attenuated macrophage accumulation, liver injury and fibrosis in acute SC. CONCLUSIONS: Peribiliary recruited macrophages are a feature of both PSC and acute and chronic murine SC models. Pharmacologic and genetic inhibition of peribiliary macrophage recruitment decreases liver injury and fibrosis in mouse SC. These observations suggest monocyte-derived macrophages contribute to the development of SC in mice and in PSC pathogenesis, and support their potential as a therapeutic target. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is an inflammatory liver disease which often progresses to liver failure. The cause of the disease is unclear and therapeutic options are limited. Therefore, we explored the role of white blood cells termed macrophages in PSC given their frequent contribution to other human inflammatory diseases. Our results implicate macrophages in PSC and PSC-like diseases in mice. More importantly, we found that pharmacologic inhibition of macrophage recruitment to the liver reduces PSC-like liver injury in the mouse. These exciting observations highlight potential new strategies to treat PSC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Guicciardi ME, Trussoni CE, Krishnan A, et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol. 2018. PMID: 29802947. doi:10.1016/j.jhep.2018.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。